Prognostic Role of CD200 in Acute Lymphoblastic Leukemia Patients
Round 1
Reviewer 1 Report
This paper proposed that CD200 can serve as a promising biomarker for the prognosis of lymphoblastic leukemia patients based on their observations in clinics. I think it is of great value for the diagnosis and treatment of this disease and of great interest to researchers in this field. Overall, the paper is well organized and its hypothesis is solidly supported by their findings. I am very glad to recommend its publication in the journal of diagnostics.
Author Response
Thanks for your supporting comments
Reviewer 2 Report
There are several points that need rephrasing/corrections
Demographic data is given in MM and Results section: should be just in the Result section.
Figure 1 is not comprehensible it its present form. Authors should either try to graphically edit it so it can elucidate a clear picture of what is being said or give a more detailed explanation. A figure should speak by itself and not need concomitant explanation.
Line 180: Sentence The best cutoff value was 60%. should be elaborated
Line 185-187: Rephrase. „In the meantime“ is not appropriate.
Line 188-190: “In the meantime” is used ever too often and in the wrong meaning.
Discussion should focus on CD200 and not characterization of B-ALL and incidence of different chromosomal and karyotype finding and comparison to published data done on much larger cohorts as this is not relevant to studied question ( the expression pattern od CD200 on leukemic B cells)
Line 340: rephrase please
Author Response
Response to Reviewer 2 Comments
Point 1: Demographic data is given in MM and Results section: should be just in the Result section
Response 1: We edited it as required.
Point 2: Figure 1 is not comprehensible it its present form. Authors should either try to graphically edit it so it can elucidate a clear picture of what is being said or give a more detailed explanation. A figure should speak by itself and not need concomitant explanation
Response 2: Navios Cytometer software Prism is used to analyze multicolor immunofluorescence samples. Prism allows you to display percentages on all phenotypic populations in a single plot. It is software derived and can be acquired in either run time or listmode.
https://www.manualslib.com/manual/1336895/Beckman-Coulter-Navios.html?page=300&term=prism&selected=3#manual
we provided this reference for more explanations related to PRISM figure
Point 3: Line 185-187: Rephrase. „In the meantime“ is not appropriate. Line 188-190: “In the meantime” is used ever too often and in the wrong meaning). We edited it as required.
Response 3: We edited it as required.
Point 4: Discussion should focus on CD200 and not characterization of B-ALL and incidence of different chromosomal and karyotype finding and comparison to published data done on much larger cohorts as this is not relevant to studied question ( the expression pattern od CD200 on leukemic B cells
Response 4: Our main aim is to find correlation between CD200 and ALL in MRD monitoring and to add CD200 in MRD panel and in National cancer institute one treatment protocol for patients in our study according to age (pediatric protocol based on total XV St. Jude protocol, while Adult received the Dana Farber Cancer Institute (DFCI) ALL/LBL protocol), and we didn't use different treatment protocols and no effect on remission is expected with expression of CD200 (Jassim et al.,2021)
{ Jassim Alwan M, Al-Mudallel SS. Prognostic impact of CD200 expression in pediatric B-cell acute lymphoblastic leukemia. Med J Babylon 2021;18:358-63.}
Point 5: Line 340: rephrase please
Response 5: we edited as required
Author Response File: 
Author Response.docx
